The bisulphite sequencing analysis of the methylation boundary [16] and of the promoter region of FMR1 disclosed that while the promoter region of FXS cells underwent a substantial demethylation, as already observed [10], the methylation boundary was not affected by treatment with 5-azadC. The gene discussed is FMR1; the disease is fragile X syndrome.